Naslov (srp)

Uticaj IL-33/ST2 signalnog puta i galektina-3 na kliničke karakteristike pacijenata sa shizofrenijom u remisiji

Autor

Minić Janićijević, Slavica, 1985-

Doprinosi

Borovčanin, Milica, 1980-
Jovanović, Ivan, 1977-
Stojanović, Zvezdana, 1972-
Jurišević, Milena, 1988-

Opis (srp)

Shizofrenija i dalje predstavlja jedan od najtežih psihotičnih,deteriorantnih poremećaja hroničnog toka, sa znatnim uticajem na emocionalni idruštveni život pacijenata, pogotovo jer su uobičajeni i somatski komorbiditeti,naročito metabolički sindrom i srčane bolesti.Cilj ove studije je bio da se ispita uticaj signalnog puta interleukina-33 isupresora tumorogeneze 2 (IL-33/ST2) i galektina-3 (Gal-3) na kliničkekarakteristike pacijenata sa shizofrenijom u remisiji. Poređene su izmerenevrednosti između grupa ispitanika, zatim je ispitivana moguća povezanost serumskihkoncentracija IL-33, sST2 i Gal-3 sa drugim merenim citokinima, kao i sa kliničkimskorovima psihijatrijskih skala procene i vrednostima biomarkerakardiometaboličkog rizika u grupi pacijenata sa shizofrenijom u remisiji.Nakon analize dobijenih rezultata, utvrđena je viša serumska koncentracijaGal-3 u grupi pacijenata sa shizofrenijom u remisiji u odnosu na kontrolnu grupuzdravih. Zatim, utvrđeno je da postoji pozitivna korelacija IL-33 saproinflamatornim citokinima IL-6, IL-23, faktorom nekroze tumora-alfa(engl. Tumor Necrosis Factor-alpha – TNF-α) i IL-1β, pozitivna korelacija sST2 saTNF-α i IL-1β, kao i pozitivna korelacija Gal-3 sa IL-23, TNF-α i sST2 u grupipacijenata sa shizofrenijom u remisiji. Utvrđena je i značajna povezanost IL-33 isST2 sa kliničkim simptomima shizofrenije, IL-33 sa kognicijom, kao i sST2 sabiomarkerima kardiometaboličkog rizika u grupi pacijenata.Možemo da zaključimo da postoji poseban uticaj IL-33/ST2 signalnog puta iGal-3 na ispitivane kliničke karakteristike kod pacijenata sa shizofrenijom uremisiji. Ova inicijalna analiza novih biomarkera zapaljenja ukazuje na mogućnostnovog pristupa u dijagnostici i tretmanu shizofrenije.

Opis (srp)

-

Opis (eng)

Schizophrenia remains one of the most severe psychotic and deteriorating disorderswith a chronic course that significantly impacts the emotional and social life of patients, oftenaccompanied by common somatic comorbidities, especially metabolic syndrome and heartdiseases.This study aimed to examine the influence of the interleukin-33 and suppressor oftumorigenesis 2 (IL-33/ST2) signaling pathway and galectin-3 (Gal-3) on the clinicalcharacteristics of patients with schizophrenia in remission. Comparison was done betweengroups, followed by an examination of the possible association of serum concentrations ofIL-33, sST2, and Gal-3 with other measured cytokines as well as with the clinical scores ofpsychiatric assessment scales and with the values of biomarkers of cardiometabolic risk in agroup of patients with schizophrenia in remission.After analyzing the results obtained from the study, it was discovered that there is ahigher serum concentration of Gal-3 in patients with schizophrenia who are in remission whencompared to healthy individuals. Additionally, there was a positive correlation between IL-33and pro-inflammatory cytokines such as IL-6, IL-23, tumor necrosis factor-alpha (TNF-α),and IL-1β. There was also a positive correlation between sST2 and TNF-α and IL-1β.Furthermore, there was a positive correlation between Gal-3 and IL-23, TNF-α, and sST2 inthe group of patients with schizophrenia in remission. In the case of IL-33 and sST2, asignificant association was found with the clinical symptoms of schizophrenia, IL-33 wasassociated with cognition and sST2 with biomarkers of cardiometabolic risk in the patientgroup.It can be concluded that there is a specific effect of the IL-33/ST2 signaling pathwayand Gal-3 on the clinical characteristics of patients with schizophrenia in remission. Thisinitial analysis of new biomarkers of inflammation indicates the possibility of a new approachin the diagnosis and treatment of schizophrenia.

Jezik

srpski

Datum

2024

Licenca

Ovo delo je licencirano pod uslovima licence
Creative Commons CC BY-ND 3.0 AT - Creative Commons Autorstvo - Bez prerada Austria License.

http://creativecommons.org/licenses/by-nd/3.0/at/legalcode